Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 5(10), 1637-1643 (2010-09-03)
AT-101 is an oral, pan Bcl-2 family protein inhibitor that has demonstrated activity in small cell lung cancer (SCLC) models. A phase I/II study was conducted combining AT-101 with topotecan in relapsed and refractory SCLC. An open-labeled multicenter phase I/II
Inhibition of pepsinogen activation by gossypol.
T D Tanksley et al.
The Journal of biological chemistry, 245(23), 6456-6461 (1970-12-10)
Studies on the nature of the inhibition by gossypol of the transformation of pepsinogen to pepsin.
R C Wong et al.
The Journal of biological chemistry, 247(5), 1625-1631 (1972-03-10)
Toxicology mechanisms and methods, 20(8), 482-486 (2010-09-17)
This study compared the two different commercially available in vitro viability assays: XTT and Alamar blue (AB), to detect anti-proliferative effects of AT-101, a cotton plant extract, on six different human carcinoma cell lines including: prostate (PC-3 and DU-145), breast
Molecular cancer research : MCR, 10(6), 673-676 (2012-04-03)
Despite real advances made in chemoimmunotherapy, chronic lymphocytic leukemia (CLL) is still an incurable disease. New therapeutic strategies based on the restoration of the cell death program seemed relevant. Some members of the Bcl-2 family are critical players in the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
